Demographics and clinical characteristics of patients with iTTP who received SARS CoV-2 vaccines at 3 university hospitals in the United States
| Characteristic . | N = 79 . |
|---|---|
| Age, median (IQR), y | 54 (42.5-66) |
| Females | 61 (77.2) |
| Males | 18 (22.8) |
| Race | |
| Black | 45 (57.0) |
| White | 33 (41.8) |
| Asian | 1 (1.2) |
| Number of iTTP episodes, median (IQR) | 1 (1-3) |
| Time from last iTTP episode to first vaccine dose, median (IQR), mo | 68.5 (29.7-144.1) |
| Vaccine type | |
| Pfizer | 47 (59.5) |
| Moderna | 27 (34.2) |
| Johnson & Johnson | 5 (6.3) |
| Prior rituximab therapy | 52 (65.8) |
| Time from most recent dose of rituximab to first dose of vaccine, median (IQR), mo | 10.5 (0.57-50.28) |
| ADAMTS13 activity prevaccination, median (IQR), % (n = 66) | 79.2 (47.2-100) |
| Characteristic . | N = 79 . |
|---|---|
| Age, median (IQR), y | 54 (42.5-66) |
| Females | 61 (77.2) |
| Males | 18 (22.8) |
| Race | |
| Black | 45 (57.0) |
| White | 33 (41.8) |
| Asian | 1 (1.2) |
| Number of iTTP episodes, median (IQR) | 1 (1-3) |
| Time from last iTTP episode to first vaccine dose, median (IQR), mo | 68.5 (29.7-144.1) |
| Vaccine type | |
| Pfizer | 47 (59.5) |
| Moderna | 27 (34.2) |
| Johnson & Johnson | 5 (6.3) |
| Prior rituximab therapy | 52 (65.8) |
| Time from most recent dose of rituximab to first dose of vaccine, median (IQR), mo | 10.5 (0.57-50.28) |
| ADAMTS13 activity prevaccination, median (IQR), % (n = 66) | 79.2 (47.2-100) |
Unless otherwise noted, data are n (%).